{"text":[[{"start":8.95,"text":"Anthropic has launched an AI product aimed at scientists and pharmaceutical groups, as the $900bn company seeks to expand its enterprise business and boost revenues ahead of its planned initial public offering."}],[{"start":22.049999999999997,"text":"The San Francisco-based start-up announced Claude Science on Tuesday, its first product dedicated to scientists, with use cases including rendering 3D protein structures and drug discovery. "}],[{"start":32.65,"text":"“We believe that the greatest opportunity to have a scaled positive impact on humanity is through our work in the sciences and in particular in life sciences and healthcare,” Eric Kauderer-Abrams, head of life sciences at Anthropic, said in an interview."}],[{"start":48.15,"text":"The release comes amid mounting pressure on Anthropic, as its rapid growth has unsettled markets and intensified concerns about AI’s impact on the economy and digital infrastructure. "}],[{"start":58.5,"text":"Its Claude Mythos model has spooked governments because of its cyber security capabilities, leading US officials to implement export controls before allowing its release to a limited number of users. "}],[{"start":70.95,"text":"Anthropic’s Claude Code product, as well as Cowork, an agentic product for non-technical users, has raised alarms in industries including software engineering, consulting and the legal sector for their ability to perform tasks autonomously, fuelling concern that some jobs could be replaced. "}],[{"start":87.5,"text":"Dario Amodei, chief executive of Anthropic, said society lacked awareness of the risks AI poses to biology compared to areas such as cyber security. Anthropic and other AI developers have cautioned that bad actors could use models to create novel diseases or bioweapons."}],[{"start":104.25,"text":"Amodei on Tuesday suggested that only vetted individuals or companies should be able to utilise powerful biological AI models that could have dangerous applications."}],[{"start":115.15,"text":"“Within pharmaceutical companies, people handle dangerous biological materials all the time, and they have their own protocols for it,” he said. “We can piggyback on those protocols [and] maybe we don’t want to give it to anyone without verifying.”"}],[{"start":129.20000000000002,"text":"Claude Science currently runs on existing models without advanced capabilities in biology. Its Mythos and Fable models, however, do carry more risk and Anthropic plans to create a trusted access programme for biology, as it has done for cyber security."}],[{"start":145.45000000000002,"text":"The new offering will expand Anthropic’s enterprise offerings to target scientists and researchers globally. "}],[{"start":152.65,"text":"“There is a really significant overhang of what is possible today relative to what most people are accessing and actually making use of,” said Kauderer-Abrams. "}],[{"start":162.1,"text":"“The primary purpose of releasing this product is to try to minimise that gap and bring all scientists in every different scientific discipline to the frontier of being able to get the most out of what’s possible,” he added."}],[{"start":175.04999999999998,"text":"Anthropic also released a new version of its Sonnet model on Tuesday, which it said had agentic performance that was close to that of its most powerful model, Opus, but at a lower cost."}],[{"start":186.7,"text":"AI has become increasingly important to drug research at big pharmaceutical companies. Eli Lilly, maker of popular weight-loss drugs, has invested in Nvidia chips and earlier this year invested in Insilico Medicine, a company specifically focused on AI for drug discovery."}],[{"start":204.7,"text":"Kauderer-Abrams said Claude Science could speed up the pre-development side of drug discovery, such as molecule design, but said the company next wanted to focus on the clinical phase. He added that Anthropic wanted to improve physical lab experiments and was exploring robotics."}],[{"start":223.04999999999998,"text":"Anthropic is expected to go public as soon as this year in a listing that could value it at more than $1tn. It closed a $65bn funding round last month at a $900bn valuation, not including the new investment."}],[{"start":237.6,"text":"Claude Science could point investors to another future revenue stream. Anthropic has signed deals with pharma companies and acquired biotech start-up Coefficient Bio in April, which used AI to drive efficiencies in drug discovery and other forms of biological research."}],[{"start":254.35,"text":"Companies including Novo Nordisk have used Claude for drug discovery, clinical documentation and regulatory submissions, as well as to speed up literature synthesis. AstraZeneca has also used Claude to scale research and development."}],[{"start":269.65,"text":"Claude Science is available on paid individual and enterprise subscriptions globally."}],[{"start":275.09999999999997,"text":"Science applications are also an important focus for rival OpenAI, which has outlined its ambitions to create an autonomous researcher to advance scientific and technological progress."}],[{"start":286.24999999999994,"text":"In April, it launched GPT‑Rosalind, a frontier reasoning model built for research in biology, drug discovery and translational medicine, which focuses on turning medical research into clinical treatments."}],[{"start":298.74999999999994,"text":"Additional reporting by Patrick Temple-West in New York"}],[{"start":308.59999999999997,"text":""}]],"url":"https://audio.ftcn.net.cn/album/a_1782873703_8932.mp3"}